J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Meta Expands AI Training With Employee Activity Tracking Tools 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
BRISBANE, Calif., March 09, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 29th Annual ROTH Conference.
The ROTH conference will be held March 12-15, 2017, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.
For more information on the conference, please visit www.roth.com/main/Page.aspx?PageID=7280.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
